858 Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
858 Therapeutics, Inc. - overview
Established
2019
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2019, 858 Therapeutics, Inc. operates as a biotechnology company that develops small molecules directed against therapeutic targets in oncology, including proteins that control Ribonucleic acid and the immune response. In September 2024, 858 Therapeutics, Inc. raised USD 50 million in series B funding led by new investor Avidity Partners, with participation from other new investors Insight Equity Partners, Mirae Asset Capital, and Alexandria Venture Investments.
Returning investors Versant Ventures, New Enterprise Associates, and Logos Capital also participated in the round. 858 Therapeutics built a platform that focuses on Ribonucleic acid (RNA) metabolism and immune sensing mechanisms to discover small-molecule therapeutics for the treatment of cancer. The platform includes a suite of proprietary in vitro biochemical and biophysical assays, as well as cellular assays. 858 Therapeutics plans to enter the clinic with its lead products that have the potential to treat cancers that are resistant to current therapies and expand its team to about 40 people within the next 18 months.
It also plans to bring leading academic scientists with specialization in the field to contribute to the company.
Current Investors
Versant Ventures, New Enterprise Associates, Cormorant Asset Management
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.8five8tx.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
858 Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.